Literature DB >> 30920124

Treatment response as predictor for brain metastasis in triple negative breast cancer: A score-based model.

Prashant Gabani1, Ashley A Weiner2, Leonel F Hernandez-Aya3, Shariq Khwaja4, Michael C Roach1, Laura L Ochoa1, Dan Mullen1, Maria A Thomas1, Melissa A Matesa1, Julie A Margenthaler5, Amy E Cyr5, Michael J Naughton3, Cynthia Ma3, Souzan Sanati6, Imran Zoberi1.   

Abstract

BACKGROUND: Triple negative breast cancer (TNBC) has worse prognosis than other subtypes of breast cancer, and many patients develop brain metastasis (BM). We developed a simple predictive model to stratify the risk of BM in TNBC patients receiving neo-adjuvant chemotherapy (NAC), surgery, and radiation therapy (RT).
METHODS: Patients with TNBC who received NAC, surgery, and RT were included. Cox proportional hazards method was used to evaluate factors associated with BM. Significant factors predictive for BM on multivariate analysis (MVA) were used to develop a risk score. Patients were divided into three risk groups: low, intermediate, and high. A receiver operating characteristic (ROC) curve was drawn to evaluate the value of the risk group in predicting BM. This predictive model was externally validated.
RESULTS: A total of 160 patients were included. The median follow-up was 47.4 months. The median age at diagnosis was 49.9 years. The 2-year freedom from BM was 90.5%. Persistent lymph node positivity, HR 8.75 (1.76-43.52, P = 0.01), and lack of downstaging, HR 3.46 (1.03-11.62, P = 0.04), were significant predictors for BM. The 2-year rate of BM was 0%, 10.7%, and 30.3% (P < 0.001) in patients belonging to low-, intermediate-, and high-risk groups, respectively. Area under the ROC curve was 0.81 (P < 0.001). This model was externally validated (C-index = 0.79).
CONCLUSIONS: Lack of downstaging and persistent lymph node positivity after NAC are associated with development of BM in TNBC. This model can be used by the clinicians to stratify patients into the three risk groups to identify those at increased risk of developing BM and potentially impact surveillance strategies.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  brain metastasis; breast cancer; neoadjuvant chemotherapy; risk score; triple negative breast cancer

Mesh:

Year:  2019        PMID: 30920124     DOI: 10.1111/tbj.13230

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  5 in total

1.  A pre-operative MRI-based brain metastasis risk-prediction model for triple-negative breast cancer.

Authors:  Xiaojie Cheng; Liang Xia; Suguang Sun
Journal:  Gland Surg       Date:  2021-09

Review 2.  Predictors of Neoadjuvant Chemotherapy Response in Breast Cancer: A Review.

Authors:  Weilin Xu; Xiu Chen; Fei Deng; Jian Zhang; Wei Zhang; Jinhai Tang
Journal:  Onco Targets Ther       Date:  2020-06-22       Impact factor: 4.147

3.  A risk stratification model for predicting brain metastasis and brain screening benefit in patients with metastatic triple-negative breast cancer.

Authors:  Mingxi Lin; Yizi Jin; Jia Jin; Biyun Wang; Xichun Hu; Jian Zhang
Journal:  Cancer Med       Date:  2020-09-18       Impact factor: 4.452

4.  Pericyte-secreted IGF2 promotes breast cancer brain metastasis formation.

Authors:  Kinga Molnár; Ádám Mészáros; Csilla Fazakas; Mihály Kozma; Fanni Győri; Zita Reisz; László Tiszlavicz; Attila E Farkas; Ádám Nyúl-Tóth; János Haskó; István A Krizbai; Imola Wilhelm
Journal:  Mol Oncol       Date:  2020-06-26       Impact factor: 6.603

5.  Evaluation of imaging findings and prognostic factors after whole-brain radiotherapy for carcinomatous meningitis from breast cancer: A retrospective analysis.

Authors:  Yukinori Okada; Tatsuyuki Abe; Mio Shinozaki; Akiko Tanaka; Mariko Kobayashi; Gomi Hiromichi; Yoshihide Kanemaki; Naoki Nakamura; Yasuyuki Kojima
Journal:  Medicine (Baltimore)       Date:  2020-07-31       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.